104.96
1.58%
-1.68
Dopo l'orario di chiusura:
104.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Amalgamated Bank Cuts Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Short Interest Update - MarketBeat
MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) to Post Q2 2024 Earnings of ($1.40) Per Share, Zacks Research Forecasts - MarketBeat
MarketBeat
Is Blueprint Medicines Corp (BPMC) positioned for future growth? – Sete News - SETE News
SETE News
Blueprint Medicines Corp [BPMC] Insider Activity: An Update for Investors – Knox Daily - Knox Daily
Knox Daily
Blueprint Medicines Corp (BPMC) presents a great opportunity, but the stock is slightly undervalued – US Post News - US Post News
US Post News
Blueprint Medicines (NASDAQ:BPMC) Research Coverage Started at Stephens - MarketBeat
MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High at $111.02 - MarketBeat
MarketBeat
Unveiling 18 Analyst Insights On Blueprint Medicines - Blueprint Medicines (NASDAQ:BPMC) - Benzinga
Benzinga
Stephens calls Blueprint Medicines its 'best idea', rates stock overweight - Investing.com South Africa
Investing.com South Africa
Stephens calls Blueprint Medicines its 'best idea', rates stock overweight - Investing.com
Investing.com
Stephens calls Blueprint Medicines its 'best idea', rates stock overweight - Investing.com India
Investing.com India
Van ECK Associates Corp Acquires 193 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Defense World
Swiss National Bank Sells 19,400 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
MarketBeat
Swiss National Bank Sells 19400 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Russell Investments Group Ltd. - Defense World
Defense World
Blueprint Medicines Co. to Post Q2 2024 Earnings of ($1.10) Per Share, Leerink Partnrs Forecasts (NASDAQ:BPMC) - MarketBeat
MarketBeat
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM - Yahoo New Zealand News
Yahoo New Zealand News
Blueprint Medicines Co. Forecasted to Earn FY2027 Earnings of $5.34 Per Share (NASDAQ:BPMC) - Defense World
Defense World
Blueprint Medicines (NASDAQ:BPMC) Upgraded by Leerink Partnrs to Market Perform - Defense World
Defense World
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand - Yahoo Finance
Yahoo Finance
Blueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 1,834 Shares - MarketBeat
MarketBeat
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand - Yahoo Finance
Yahoo Finance
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Company Announcement ... - Financial Times
Financial Times
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Zacks Investment Research
An analyst sees good growth prospects for Blueprint Medicines Corp (BPMC) – Sete News - SETE News
SETE News
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
Zacks Investment Research
StockNews.com Upgrades Blueprint Medicines (NASDAQ:BPMC) to “Hold” - Defense World
Defense World
Barclays Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $75.00 - Defense World
Defense World
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $135.00 at HC Wainwright - Defense World
Defense World
Blueprint Medicines (NASDAQ:BPMC) Receives Buy Rating from Needham & Company LLC - Defense World
Defense World
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Zacks Investment Research
Blueprint Medicines (NASDAQ:BPMC) Raised to Hold at StockNews.com - MarketBeat
MarketBeat
Blueprint Medicines: Q1 Earnings Snapshot - Milford Mirror
Milford Mirror
Earnings call: Blueprint Medicines raises AYVAKIT guidance amid growth - Investing.com
Investing.com
Blueprint Medicines Corp: Navigating Market Fluctuations with a 6.49B Market Cap – Invest Chronicle - The InvestChronicle
The InvestChronicle
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Blueprint Medicines (NASDAQ:BPMC) Rating Reiterated by Needham & Company LLC - MarketBeat
MarketBeat
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
Zacks Investment Research
Organon (OGN) Gears Up to Report Q1 Earnings: What's in Store?
Zacks Investment Research
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
Zacks Investment Research
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Zacks Investment Research
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
MarketBeat
Jackson Creek Investment Advisors LLC Makes New $1.43 Million Investment in Blueprint Medicines Co. (NASDAQ ... - MarketBeat
MarketBeat
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
Zacks Investment Research
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
Zacks Investment Research
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts - Blueprint Medicines (NASDAQ:BPMC) - Benzinga
Benzinga
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks Investment Research
Capitalizzazione:
|
Volume (24 ore):